GAITHERSBURG, Md., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver and cardiometabolic ...

Appointment recognizes Mr. Durso’s extensive commercial expertise as Altimmune prepares for Phase 3 development of pemvidutide in MASH Mitchel Sayare, Ph.D., to remain on the Board as Independent ...

Under these assumptions, Altimmune could have an estimated revenue of around $2.3B ($77B X 3 %). In my opinion, this could be a conservative estimate of the possible Pemvidutide sales in 6 years.

We expect investors to focus on Altimmune’s ALT progress in the studies evaluating its lead pipeline candidate, pemvidutide, when it reports second-quarter 2025 results. Since ALT lacks a marketed ...

Altimmune has gone all-in on pemvidutide, a GLP-1/glucagon dual receptor agonist, and has the potential to secure blockbuster status, but they run the risk of regulatory failure.

The firm, which argues that pemvidutide "appears differentiated among GLP-1 compounds," reiterates a Buy rating and $12 price target on Altimmune shares.Published first on TheFly – the ultimate ...

Altimmune says pemvidutide given ‘clean safety bill of health’ by FDA TipRanks Nov. 11, 2024, 01:45 PM ...

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual ...

--Altimmune, Inc., a clinical-stage biopharmaceutical company, today announced that new data on the anti-inflammatory and anti-fibrotic properties of pemvidutide in subjects with metabolic ...

Altimmune said it presented data from the 48-week Phase 2 MOMENTUM clinical trial of pemvidutide, including the results of a recently completed body composition analysis at the American Diabetes ...

Altimmune's phase 2 trial successfully demonstrated that pemvidutide can help achieve meaningful weight loss while simultaneously maintaining healthy muscle mass in most patients tested.

In 2019, Altimmune purchased pemvidutide from Spitfire Pharma for $5 million upfront, with an additional $88 million payable in sales and development milestones if the medication becomes effective.